Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IQVIA Backs Global Generics & Biosimilars Awards 2020

Healthcare Analytics And Technology Firm Is Headline Sponsor

Executive Summary

IQVIA has joined the Global Generics & Biosimilars Awards 2020 as headline sponsor, while West AccelTRA will lend its backing to the awards as a category sponsor. The awards, which are free to enter and attend, will take place in October 2020 in Milan, Italy.

You may also be interested in...



Milan Will Host The Global Generics & Biosimilars Awards 2020

Informa Pharma Intelligence has officially launched the seventh Global Generics & Biosimilars Awards, which will take place in October 2020 in Milan, Italy.

Isatuximab EU Approval Decision Due

Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.

Mylan Gives Up Exclusivity For US Kaletra Rival

Mylan has waived US exclusivity rights to its generic version of AbbVie’s Kaletra, which is being investigated as a treatment for COVID-19, after a week of activity that has seen Israel move to compulsory-license generic versions of the brand and the originator step back from enforcing related intellectual property worldwide.

Topics

UsernamePublicRestriction

Register

GB149707

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel